Literature DB >> 19856064

The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits.

Hiroshi Eguchi1, Hiroshi Shiota, Susumu Oguro, Toshio Kasama.   

Abstract

The purpose of this study was to investigate an experimental model of methicillin-resistant Staphylococcus aureus (MRSA) keratitis, and to evaluate the inhibitory effect of vancomycin ointment on the manifestation of keratitis in this model. For the development of the MRSA keratitis model, 16 rabbits received 0.3-ml intrastromal injections of 1 x 10(7) colony forming units/ml MRSA inoculated to each of their corneas. After the MRSA inoculation, the rabbits were examined for a period of 14 days. Vehicle only was applied to each left eye for 2 days as an experimental control. Prototype vancomycin ointments, at concentrations of 0.03%, 0.1%, 0.3%, and 1.0%, were applied to each right eye for 2 days. The treatment commenced immediately after the MRSA inoculation and was administered five times a day at 2-h intervals. Four rabbits were used for each vancomycin ointment concentration. Anterior segments were examined daily, and the minimum inhibitory concentration of vancomycin (percentage in the ointment) for treating MRSA keratitis was determined on day 2. On day 14, no recurrences of infection were observed in the eyes that had not exhibited keratitis on day 2. Forty-eight hours post-inoculation, all left eyes demonstrated severe conjunctivitis, stromal infiltrates at injection sites, and fibroid reactions in the anterior chamber. MRSA keratitis was completely inhibited by 0.3% and 1.0% vancomycin ointments. Although the 0.1% ointment generally could prevent keratitis, punctate infiltrates were found in some eyes. Numerous infiltrates were found in eyes treated with 0.03% ointment. In conclusion, the present study substantiates the view that vancomycin ointment has a potent inhibitory effect upon the manifestations of MRSA keratitis, and indicates that a 0.3% concentration is necessary for effective treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856064     DOI: 10.1007/s10156-009-0708-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  7 in total

1.  Local treatment of methicillin-resistant Staphylococcus aureus conjunctivitis with short-term high-concentrated minocycline ointment.

Authors:  Eriko Ikeda; Tomoyuki Inoue; Seishi Asari; Masahiro Toyokawa; Yuichi Hori; Naoyuki Maeda
Journal:  Jpn J Ophthalmol       Date:  2011-07-26       Impact factor: 2.447

2.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

Review 3.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

4.  Vancomycin Ophthalmic Ointment 1% for methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis infections: a case series.

Authors:  Chie Sotozono; Masahiko Fukuda; Masao Ohishi; Keiko Yano; Hideki Origasa; Yoshinori Saiki; Yoshikazu Shimomura; Shigeru Kinoshita
Journal:  BMJ Open       Date:  2013-01-29       Impact factor: 2.692

5.  Prevalence of drug resistance and culture-positive rate among microorganisms isolated from patients with ocular infections over a 4-year period.

Authors:  Yusuke Shimizu; Hiroshi Toshida; Rio Honda; Asaki Matsui; Toshihiko Ohta; Yousuke Asada; Akira Murakami
Journal:  Clin Ophthalmol       Date:  2013-04-09

6.  Efficacy of Caltropis procera and Ficus sycomorus extracts in treating MRSA (methicillin-resistant Staphylococcus aureus)-keratitis in rabbit.

Authors:  Waiel F Sayed; Wesam M A Salem; Mohie A M Haridy; Ne'mat H Hassan
Journal:  EXCLI J       Date:  2015-06-16       Impact factor: 4.068

Review 7.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.

Authors:  Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2019-09-06       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.